PRNewsWire · 22 Sept 2026positive
Lucid Diagnostics, a subsidiary of PAVmed, announced advances in payment, billing, and coding pathways for its EsoGuard and EsoCheck products. A Medicare advisory panel recommended keeping EsoGuard's original gapfill payment basis under the Clinical Laboratory Fee Schedule, the AMA approved a new Category III CPT code for non-endoscopic cell collection with EsoCheck, and a proposed ICD-10-CM diagnosis code for positive EsoGuard results received a favorable response from the CDC/NCHS committee.
Why it matters — These coding, billing, and payment milestones could help broaden reimbursement and adoption for PAVmed's subsidiary products.
Seeking Alpha · 14 Aug 2026neutral
PAVmed Inc. held its second-quarter 2026 earnings call, and Seeking Alpha published the full transcript of the discussion. The transcript covers the company's Q2 2026 results and management commentary from the call.
Why it matters — PAVmed watchers would care because the earnings call transcript provides direct insight into the company's latest quarterly performance and management's own commentary on its operations.
PRNewsWire · 14 Aug 2026positive
PAVmed provided a business update and reported financial results for the second quarter ended June 30, 2026. The update noted that Veris Health accelerated commercial engagement with OSU-The James, its implantable physiological monitor achieved development milestones toward an upcoming FDA submission, and Lucid Diagnostics secured its first laboratory benefit manager coverage policy for EsoGuard. A conference call and webcast were held August 14, 2026.
Why it matters — PAVmed watchers would care because these milestones mark tangible progress for its subsidiaries, including Veris Health advancing its monitor toward an FDA submission and Lucid Diagnostics gaining its first coverage policy for EsoGuard.
PRNewsWire · 13 Aug 2026positive
Lucid Diagnostics, a subsidiary of PAVmed, reported second quarter 2026 financial results with $1.5 million in revenue, processed 2,770 EsoGuard tests, and secured its first laboratory benefit manager coverage policy for EsoGuard.
Why it matters — As a wholly owned subsidiary of PAVmed, Lucid's revenue growth and insurance coverage milestone directly impact PAVmed's consolidated financial performance and the valuation of its key asset.
PRNewsWire · 5 Aug 2026positive
Lucid Diagnostics, a subsidiary of PAVmed, announced that Concert issued a positive coverage policy effective July 2026 for non-invasive screening of esophageal precancer and cancer, recognizing EsoGuard as the only esophageal precancer test meeting its coverage criteria. The policy can be adopted by Concert's client health plans.
Why it matters — A positive commercial coverage policy from Concert could expand access to Lucid's EsoGuard test across multiple health plans, which is significant for PAVmed given Lucid is its subsidiary.
